1991;325:293 302. 11. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative ef- fects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart fail- ure. ATLAS Study Group. Circulation. 1999;100:2312 8. 12. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunc- tion after myocardial infarction. Results of the survival and ven- tricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669 77. 13. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lan- cet. 1993;342:821 8. 14. K ber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Tran- dolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670 6. 15. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667 75. Heart Failure Focused Update on Pharmacological Therapy CLINICAL STATEMENTS AND GUIDELINES 16. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, capto- pril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349: 1893 906. 17. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lan- cet. 2009;374:1840 8. 18. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesar- tan on mortality and morbidity in patients with chronic heart fail- ure: the CHARM-Overall programme. Lancet. 2003;362:759 66. 19. McMurray JJV, Packer M, Desai AS, et al. 